Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?
Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions.
https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Links:
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology? | Rheum…
https://buff.ly/cZG6wyh
Dec-29-2025


